On one hand, it may target mechanisms specific to certain conditions, such as preventing beta-amyloid formation in Alzheimer’s disease [9] or alpha-synuclein aggregation in Parkinson’s disease [26]. The gene discussed is SNCA; the disease is early-onset autosomal dominant Alzheimer disease.